Zuzanna Lechowska
Zuzanna Lechowska has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Kafara
Jagiellonian University Medical College, Krakow, Poland
10 shared publications - Dominika Jurczak
Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
10 shared publications - Donata Kowalczyk
5th Military Hospital with Polyclinic in Cracow, Krakow, Poland
10 shared publications - Julia Koronczok-Matusiak
J. Gromkowski Voivodship Specialist Hospital in Wrocław, Wrocław, Poland
10 shared publications - Katarzyna Michta
Medical University of Gdansk, Gdansk, Poland
10 shared publications - Konrad Kulka
Municipal Hospital in Zabrze, Zabrze, Poland
10 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE IMPACT OF STRESS ON THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in the identification and treatment of classic risk factors. Accumulating evidence suggests that psychosocial stress may play a significant role in the development and progression of CVD through biological and behavioral mechanisms. Objective: The aim of the study was to summarize the current knowledge on the relationship between psychosocial stress and cardiovascular diseases, with particular emphasis on the pathophysiological mechanisms underlying this relationship and the possibilities of stress reduction in the prevention and treatment of CVD. Methods: A narrative literature review was conducted using PubMed, Nature Reviews, and Google Scholar. Scientific publications published primarily between 2014 and 2025 were analyzed, including systematic reviews, meta-analyses, cohort studies, clinical trials, experimental studies, and epidemiological reports. Papers on the biological and psychological mechanisms linking psychosocial stress with cardiovascular diseases and interventions aimed at reducing stress were included. Results: Psychosocial stress should be viewed as a multidimensional risk factor for cardiovascular disease, potentially contributing to both its development and progression. Incorporating stress assessment and implementing effective stress reduction strategies may be a valuable complement to current CVD prevention and treatment strategies. Further research involving large patient populations is needed to determine the role of stress-reducing interventions in routine cardiac care.
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE IMPACT OF STRESS ON THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in the identification and treatment of classic risk factors. Accumulating evidence suggests that psychosocial stress may play a significant role in the development and progression of CVD through biological and behavioral mechanisms. Objective: The aim of the study was to summarize the current knowledge on the relationship between psychosocial stress and cardiovascular diseases, with particular emphasis on the pathophysiological mechanisms underlying this relationship and the possibilities of stress reduction in the prevention and treatment of CVD. Methods: A narrative literature review was conducted using PubMed, Nature Reviews, and Google Scholar. Scientific publications published primarily between 2014 and 2025 were analyzed, including systematic reviews, meta-analyses, cohort studies, clinical trials, experimental studies, and epidemiological reports. Papers on the biological and psychological mechanisms linking psychosocial stress with cardiovascular diseases and interventions aimed at reducing stress were included. Results: Psychosocial stress should be viewed as a multidimensional risk factor for cardiovascular disease, potentially contributing to both its development and progression. Incorporating stress assessment and implementing effective stress reduction strategies may be a valuable complement to current CVD prevention and treatment strategies. Further research involving large patient populations is needed to determine the role of stress-reducing interventions in routine cardiac care.
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE GUT-BRAIN AXIS: EXPLORING THE IMPACT OF GUT MICROBIOTA ON MENTAL HEALTH
The microbiota-gut-brain axis represents a complex bidirectional communication network linking the intestinal microbiota with the central nervous system through neural, endocrine, immune, and metabolic pathways. Growing evidence suggests that alterations in gut microbiota composition may contribute to the pathophysiology of several mental disorders, including depression, anxiety disorders, bipolar disorder, and attention-deficit/hyperactivity disorder. This review aims to summarize current knowledge on the mechanisms by which gut microbiota may influence mental health and to discuss microbiota-targeted therapeutic approaches. Dysbiosis may affect brain function through vagus nerve signaling, hypothalamic-pituitary-adrenal axis activation, increased intestinal permeability, systemic inflammation, cytokine release, altered neurotransmitter metabolism, and reduced production of short-chain fatty acids. Studies indicate that individuals with psychiatric disorders often show reduced microbial diversity, depletion of beneficial anti-inflammatory and butyrate-producing bacteria, and enrichment of pro-inflammatory microbial taxa. These changes may promote neuroinflammation, oxidative stress, impaired stress regulation, and disturbances in serotonin, dopamine, gamma-aminobutyric acid, and tryptophan-related pathways. The review also examines the potential role of probiotics, prebiotics, synbiotics and fecal microbiota transplantation in modulating the gut microbiome and improving psychiatric symptoms. Although some clinical and experimental findings suggest beneficial effects, especially in depression and anxiety, the available evidence remains heterogeneous. Further well-designed, long-term clinical studies, are recquired to clarify causal mechanisms, identify effective microbial interventions, and determine their place in mental health prevention and treatment.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE GUT-BRAIN AXIS: EXPLORING THE IMPACT OF GUT MICROBIOTA ON MENTAL HEALTH
The microbiota-gut-brain axis represents a complex bidirectional communication network linking the intestinal microbiota with the central nervous system through neural, endocrine, immune, and metabolic pathways. Growing evidence suggests that alterations in gut microbiota composition may contribute to the pathophysiology of several mental disorders, including depression, anxiety disorders, bipolar disorder, and attention-deficit/hyperactivity disorder. This review aims to summarize current knowledge on the mechanisms by which gut microbiota may influence mental health and to discuss microbiota-targeted therapeutic approaches. Dysbiosis may affect brain function through vagus nerve signaling, hypothalamic-pituitary-adrenal axis activation, increased intestinal permeability, systemic inflammation, cytokine release, altered neurotransmitter metabolism, and reduced production of short-chain fatty acids. Studies indicate that individuals with psychiatric disorders often show reduced microbial diversity, depletion of beneficial anti-inflammatory and butyrate-producing bacteria, and enrichment of pro-inflammatory microbial taxa. These changes may promote neuroinflammation, oxidative stress, impaired stress regulation, and disturbances in serotonin, dopamine, gamma-aminobutyric acid, and tryptophan-related pathways. The review also examines the potential role of probiotics, prebiotics, synbiotics and fecal microbiota transplantation in modulating the gut microbiome and improving psychiatric symptoms. Although some clinical and experimental findings suggest beneficial effects, especially in depression and anxiety, the available evidence remains heterogeneous. Further well-designed, long-term clinical studies, are recquired to clarify causal mechanisms, identify effective microbial interventions, and determine their place in mental health prevention and treatment.
- Open Access
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
NATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessNATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73985
Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review
Background: Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.Aim: To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.Results: Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.Conclusions: Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73985
Open AccessTargeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review
Background: Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.Aim: To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.Results: Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.Conclusions: Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.
- Open Access
- 4 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 65, 73982
Pharmacological Rescue After Bariatric Surgery Failure: The Role of GLP-1 Receptor Agonists in Weight Regain Management
Background:Obesity is a chronic, multifactorial disease with rapidly growing global prevalence. Bariatric surgery remains the most effective intervention for long-term weight reduction and improvement of obesity-related comorbidities; however, 16 - 37% of patients experience inadequate weight loss or weight regain, prompting the search for less invasive pharmacological strategies. Aim:To review the efficacy and safety of GLP-1 receptor agonists in adults after bariatric surgery presenting with insufficient weight loss or weight regain. Material and methods:A narrative literature review was conducted using medical databases and current guidelines, including original and review articles in English involving adult post-bariatric patients treated with GLP-1 receptor agonists, reporting weight-related outcomes and safety data. Results:Liraglutide 3.0 mg achieved additional weight loss of approximately 5 - 6% over 6 - 8 months, with early onset of effect and comparable efficacy across surgical techniques. Once-weekly semaglutide (0.5 mg) demonstrated weight loss of 10.3% at 6 months. After 12 months of GLP-1 receptor agonist therapy (liraglutide or semaglutide combined), median total body weight loss reached 11.2%. Preliminary data on tirzepatide suggest superior efficacy: 15.5% weight loss at 6 months versus 10.3% with semaglutide after sleeve gastrectomy. Adverse events were predominantly mild to moderate gastrointestinal symptoms. Conclusions:GLP-1 receptor agonists represent a promising, less invasive option for post-bariatric weight management and should be considered before revisional surgery in appropriately selected patients. Larger randomised studies - particularly with tirzepatide - are needed to define optimal drug choice, timing, and patient selection.
- 4 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 65, 73982
Open AccessPharmacological Rescue After Bariatric Surgery Failure: The Role of GLP-1 Receptor Agonists in Weight Regain Management
Background:Obesity is a chronic, multifactorial disease with rapidly growing global prevalence. Bariatric surgery remains the most effective intervention for long-term weight reduction and improvement of obesity-related comorbidities; however, 16 - 37% of patients experience inadequate weight loss or weight regain, prompting the search for less invasive pharmacological strategies. Aim:To review the efficacy and safety of GLP-1 receptor agonists in adults after bariatric surgery presenting with insufficient weight loss or weight regain. Material and methods:A narrative literature review was conducted using medical databases and current guidelines, including original and review articles in English involving adult post-bariatric patients treated with GLP-1 receptor agonists, reporting weight-related outcomes and safety data. Results:Liraglutide 3.0 mg achieved additional weight loss of approximately 5 - 6% over 6 - 8 months, with early onset of effect and comparable efficacy across surgical techniques. Once-weekly semaglutide (0.5 mg) demonstrated weight loss of 10.3% at 6 months. After 12 months of GLP-1 receptor agonist therapy (liraglutide or semaglutide combined), median total body weight loss reached 11.2%. Preliminary data on tirzepatide suggest superior efficacy: 15.5% weight loss at 6 months versus 10.3% with semaglutide after sleeve gastrectomy. Adverse events were predominantly mild to moderate gastrointestinal symptoms. Conclusions:GLP-1 receptor agonists represent a promising, less invasive option for post-bariatric weight management and should be considered before revisional surgery in appropriately selected patients. Larger randomised studies - particularly with tirzepatide - are needed to define optimal drug choice, timing, and patient selection.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
FRAILTY SYNDROME IN CLINICAL NEUROLOGY: A COMPREHENSIVE REVIEW OF NERVOUS SYSTEM PATHOPHYSIOLOGY, PROGNOSIS IN SELECTED CONDITIONS, AND SOCIO-TECHNOLOGICAL PERSPECTIVES
Background: Neurological conditions are now the leading cause of disability worldwide. Frailty syndrome, defined as a multisystemic state of physiological impairment, often predicts clinical outcomes more accurately than chronological age. Objective: This review examines the molecular pathophysiology of neuro-frailty, its prognostic significance in acute ischemic stroke, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as the integration of emerging diagnostic technologies. Methodology: A comprehensive review of English-language articles published from 2001 to 2026 in PubMed, Scopus, and Cochrane was conducted. Grey literature and animal studies were excluded from the analysis. The synthesis focused on meta-analyses and human-based research connecting artificial intelligence diagnostics, fluid biomarkers, and clinical neurology. Results: Neuro-frailty is associated with the phenomenon of inflammaging, the secretory ageing-associating phenotype (SASP), and progressive mitochondrial dysfunction. The presence of pre-existing frailty also elevates the risk of unfavorable functional recovery (mRS > 2) in acute phase of ischaemic stroke by 3.11 times. In MS, ongoing neurodegeneration accelerates biological ageing, often resulting in premature frailty. The sarcopenia-frailty axis in Parkinson’s disease affects over 35% of patients and significantly increases the risk of recurrent falls. Modern diagnostic methods now enable objective and precise quantification of this impairment. Conclusions: Frailty is a dynamic clinical condition that is possible to reverse. The transition from age-based metrics to AI-powered biological screening enables a personalized approach to care by clinicians. These targeted strategies are essential for maintaining neurological functions and reducing socio-economic consequences of ageing.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessFRAILTY SYNDROME IN CLINICAL NEUROLOGY: A COMPREHENSIVE REVIEW OF NERVOUS SYSTEM PATHOPHYSIOLOGY, PROGNOSIS IN SELECTED CONDITIONS, AND SOCIO-TECHNOLOGICAL PERSPECTIVES
Background: Neurological conditions are now the leading cause of disability worldwide. Frailty syndrome, defined as a multisystemic state of physiological impairment, often predicts clinical outcomes more accurately than chronological age. Objective: This review examines the molecular pathophysiology of neuro-frailty, its prognostic significance in acute ischemic stroke, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as the integration of emerging diagnostic technologies. Methodology: A comprehensive review of English-language articles published from 2001 to 2026 in PubMed, Scopus, and Cochrane was conducted. Grey literature and animal studies were excluded from the analysis. The synthesis focused on meta-analyses and human-based research connecting artificial intelligence diagnostics, fluid biomarkers, and clinical neurology. Results: Neuro-frailty is associated with the phenomenon of inflammaging, the secretory ageing-associating phenotype (SASP), and progressive mitochondrial dysfunction. The presence of pre-existing frailty also elevates the risk of unfavorable functional recovery (mRS > 2) in acute phase of ischaemic stroke by 3.11 times. In MS, ongoing neurodegeneration accelerates biological ageing, often resulting in premature frailty. The sarcopenia-frailty axis in Parkinson’s disease affects over 35% of patients and significantly increases the risk of recurrent falls. Modern diagnostic methods now enable objective and precise quantification of this impairment. Conclusions: Frailty is a dynamic clinical condition that is possible to reverse. The transition from age-based metrics to AI-powered biological screening enables a personalized approach to care by clinicians. These targeted strategies are essential for maintaining neurological functions and reducing socio-economic consequences of ageing.
- Open Access
- 23 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
VASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Background: Vascular cognitive impairment (VCI) is a major contributor to age-associated cognitive decline, both independently and as a contributor to mixed dementia syndromes. Despite many years of research, an approved therapy has not yet been identified. Methods: We reviewed preventive and therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. Results: VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. Conclusion: Early and effective management of cerebrovascular risk factors, particularly beginning in midlife, plays a crucial role in lowering the likelihood of developing neurodegenerative conditions such a vascular cognitive impairment and other related dementias. Ginkgo biloba extracts and acetylcholinesterase inhibitors have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low.
- 23 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessVASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Background: Vascular cognitive impairment (VCI) is a major contributor to age-associated cognitive decline, both independently and as a contributor to mixed dementia syndromes. Despite many years of research, an approved therapy has not yet been identified. Methods: We reviewed preventive and therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. Results: VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. Conclusion: Early and effective management of cerebrovascular risk factors, particularly beginning in midlife, plays a crucial role in lowering the likelihood of developing neurodegenerative conditions such a vascular cognitive impairment and other related dementias. Ginkgo biloba extracts and acetylcholinesterase inhibitors have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low.
- Open Access
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
TRASTUZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF HER2-POSITIVE NEOPLASM
Treating cancers is a challenge that many scientists from around the world face every day. Thanks to the scientific advances, cancers are now divided not only by the organ they affect, but also into subtypes such as histological and molecular. Small molecules present on cancer cells have become the target of molecular drugs, making cancer treatment even more personalized for specific type. One of them is the use of trastuzumab - a targeted monoclonal antibody used in the treatment of cancers with overexpression of the HER2 protein on cell membrane. Trastuzumab inhibits the growth of cancer cells by blocking HER2 receptors. This mechanism is used in the treatment of HER2-positive breast and stomach cancer. In clinical trials, trastuzumab has been shown to have significantly higher rates of disease-free survival, absolute survival rate, median overall survival, progression-free survival and the duration of response than similar therapies without it. This makes it promising and useful in anticancer therapy in some neoplasm types. In addition, the safety profile has been checked and assessed in many respects, taking into account the side effects that this drug causes.
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTRASTUZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF HER2-POSITIVE NEOPLASM
Treating cancers is a challenge that many scientists from around the world face every day. Thanks to the scientific advances, cancers are now divided not only by the organ they affect, but also into subtypes such as histological and molecular. Small molecules present on cancer cells have become the target of molecular drugs, making cancer treatment even more personalized for specific type. One of them is the use of trastuzumab - a targeted monoclonal antibody used in the treatment of cancers with overexpression of the HER2 protein on cell membrane. Trastuzumab inhibits the growth of cancer cells by blocking HER2 receptors. This mechanism is used in the treatment of HER2-positive breast and stomach cancer. In clinical trials, trastuzumab has been shown to have significantly higher rates of disease-free survival, absolute survival rate, median overall survival, progression-free survival and the duration of response than similar therapies without it. This makes it promising and useful in anticancer therapy in some neoplasm types. In addition, the safety profile has been checked and assessed in many respects, taking into account the side effects that this drug causes.
- Open Access
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
ARTIFICIAL INTELLIGENCE-ASSISTED GASTROSCOPY IN EARLY GASTRIC CANCER PREVENTION: A REVIEW OF CURRENT OPPORTUNITIES AND FUTURE TECHNOLOGICAL CHALLENGES
Endoscopic examination plays a crucial role in the secondary prevention of gastric cancer. However, its effectiveness is often limited by the subjective nature of assessment and the risk of missing neoplastic lesions. The use of deep learning (DL) and machine learning (ML) models allows for a significant improvement in the quality of endoscopic diagnosis of early gastric cancer. Real-time systems increase the sensitivity of the examination and reduce skill-based differences between endoscopists. They also enable precise assessment of tumor invasion depth, which is essential for qualifying patients for minimally invasive treatment. Explainable artificial intelligence (XAI) methods and ML algorithms are gaining increasing importance as they enhance the transparency of the diagnostic process. Despite promising data, the full implementation of AI systems in endoscopy faces challenges such as susceptibility to imaging artifacts, the risk of model overfitting, and regulatory hurdles. A key issue remains the development of representative, multicenter training image databases and the conduct of prospective clinical trials, which may revolutionize standards of care. The aim of this article is to discuss the role of AI-assisted gastroscopy in the prevention of early gastric cancer, with particular emphasis on its potential in population-based screening programs. The paper presents current clinical data and analyzes the benefits and challenges associated with implementing these technologies into routine clinical practice.
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessARTIFICIAL INTELLIGENCE-ASSISTED GASTROSCOPY IN EARLY GASTRIC CANCER PREVENTION: A REVIEW OF CURRENT OPPORTUNITIES AND FUTURE TECHNOLOGICAL CHALLENGES
Endoscopic examination plays a crucial role in the secondary prevention of gastric cancer. However, its effectiveness is often limited by the subjective nature of assessment and the risk of missing neoplastic lesions. The use of deep learning (DL) and machine learning (ML) models allows for a significant improvement in the quality of endoscopic diagnosis of early gastric cancer. Real-time systems increase the sensitivity of the examination and reduce skill-based differences between endoscopists. They also enable precise assessment of tumor invasion depth, which is essential for qualifying patients for minimally invasive treatment. Explainable artificial intelligence (XAI) methods and ML algorithms are gaining increasing importance as they enhance the transparency of the diagnostic process. Despite promising data, the full implementation of AI systems in endoscopy faces challenges such as susceptibility to imaging artifacts, the risk of model overfitting, and regulatory hurdles. A key issue remains the development of representative, multicenter training image databases and the conduct of prospective clinical trials, which may revolutionize standards of care. The aim of this article is to discuss the role of AI-assisted gastroscopy in the prevention of early gastric cancer, with particular emphasis on its potential in population-based screening programs. The paper presents current clinical data and analyzes the benefits and challenges associated with implementing these technologies into routine clinical practice.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
SELECTED DIETARY SUPPLEMENTS AND THEIR IMPACT ON ENDURANCE AND RECOVERY IN RUNNERS: A SYSTEMATIC REVIEW
Running places high metabolic, neuromuscular and physiological demands on athletes, stimulating interest in nutritional supplements that may enhance performance and delay fatigue. Various ergogenic aids - including caffeine, creatine, β-alanine and beetroot-derived nitrates, have been investigated, yet their relative effectiveness across different running modalities remains unclear. A systematic search of PubMed (2010–2025) using the terms “supplementation” and “running” identified 234 records. After screening titles, abstracts and full texts according to predefined criteria, 26 studies evaluating single-ingredient supplements and reporting running-specific outcomes were included. A narrative synthesis was conducted due to heterogeneity in study designs and performance tests. Caffeine consistently improved running performance across sprint, repeated and endurance efforts by extending time to exhaustion, enhancing acceleration and increasing metabolic activation without elevating physiological strain. Creatine improved mean power, maintained running speed and reduced fatigue during short and repeated high-intensity efforts, with limited effects in endurance running. β-alanine increased muscle carnosine content and enhanced tolerance to high-intensity or fatigue-inducing exercise, while producing modest improvements during submaximal workloads. Beetroot-derived nitrates improved performance primarily in short, intense and intermittent running, especially in moderately trained athletes, whereas betalains supported recovery through antioxidant and anti-inflammatory mechanisms. Caffeine, creatine, β-alanine and beetroot-derived supplements all exert ergogenic effects, but their benefits are exercise-specific. Matching the supplement to the running demands and athlete characteristics is essential for maximizing performance outcomes.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessSELECTED DIETARY SUPPLEMENTS AND THEIR IMPACT ON ENDURANCE AND RECOVERY IN RUNNERS: A SYSTEMATIC REVIEW
Running places high metabolic, neuromuscular and physiological demands on athletes, stimulating interest in nutritional supplements that may enhance performance and delay fatigue. Various ergogenic aids - including caffeine, creatine, β-alanine and beetroot-derived nitrates, have been investigated, yet their relative effectiveness across different running modalities remains unclear. A systematic search of PubMed (2010–2025) using the terms “supplementation” and “running” identified 234 records. After screening titles, abstracts and full texts according to predefined criteria, 26 studies evaluating single-ingredient supplements and reporting running-specific outcomes were included. A narrative synthesis was conducted due to heterogeneity in study designs and performance tests. Caffeine consistently improved running performance across sprint, repeated and endurance efforts by extending time to exhaustion, enhancing acceleration and increasing metabolic activation without elevating physiological strain. Creatine improved mean power, maintained running speed and reduced fatigue during short and repeated high-intensity efforts, with limited effects in endurance running. β-alanine increased muscle carnosine content and enhanced tolerance to high-intensity or fatigue-inducing exercise, while producing modest improvements during submaximal workloads. Beetroot-derived nitrates improved performance primarily in short, intense and intermittent running, especially in moderately trained athletes, whereas betalains supported recovery through antioxidant and anti-inflammatory mechanisms. Caffeine, creatine, β-alanine and beetroot-derived supplements all exert ergogenic effects, but their benefits are exercise-specific. Matching the supplement to the running demands and athlete characteristics is essential for maximizing performance outcomes.